NeuroNEXT Clinical Trials at Swedish

NeuroNEXT at Swedish Neuroscience Institute (SNI) is one of only two Pacific Northwest sites for a nationwide consortium of 25 centers that conduct clinical trials for patients with diseases of the nervous system. The NeuroNEXT consortium is sponsored by the National Institute of Neurological Disorders and Stroke. Site Principal Investigator for NeuroNEXT at Swedish is Dr. James Bowen.

New NeuroNEXT Clinical Trials

NN105 – SRX246: Safety, Tolerability, and Activity in Irritable Subjects with Huntington’s Disease (STAIR)
This study is being done to find out whether a new investigational drug called SRX246 might be useful to Huntington’s Disease (HD) patients who sometimes feel irritable, angry, or even aggressive. This study is a placebo-controlled clinical trial and will compare the study drug (SRX246) to a placebo. Participants have a 2 out of 3 chance of getting study drug and a 1 out of 3 chance of getting placebo; neither the participant nor the doctor will know whether a participant is getting study drug or placebo. Principal Investigator for this study is Dr. Rosalind Chuang of the Movement Disorders clinic at Swedish Medical Center, Cherry Hill. For more information on this study please contact Research Coordinator Becky Wood at 206-320-7115 or by email at

Ongoing NeuroNEXT Clinical Trials Update

NN103 – Beat MG: B Cell Targeted Treatment in Myasthenia Gravis
The NN103 study has met its enrollment goals and thus is closed to new participants.

NN102 – Sprint MS
The Sprint MS study also met its enrollment goals. Participants enrolled at Swedish continue in the study follow-up visits.

Information on these NeuroNEXT studies, as well as other clinical trials being done in the United States, can be found at the Web site.

About NeuroNEXT

The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke’s (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders.

The NeuroNEXT program aims to

  • Provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC).
  • Support scientifically sound, possibly biomarker-informed, exploratory clinical trials that provide data for clear go/no-go decisions.
  • Energize and mobilize federal, industry, foundations and patient advocacy partners by leveraging existing relationships between NINDS and NeuroNEXT to organize high impact exploratory clinical trials for neurological disorders.
  • Expand the pool of experienced clinical investigators and research staff who are prepared to be leaders of multicenter clinical research trials.
  • Working with NeuroNEXT is a cooperative venture between NINDS, the NeuroNEXT network and the applicant.

Questions About NeuroNEXT at Swedish?

Please contact Research Coordinator Becky Wood at 206-320-7115 or by email at You can also get general information about NeuroNEXT from the NeuroNEXT web site.

NeuroNEXT Signup